ClinicalTrials.gg
RecruitingNCT07937410cSDH RCTUpdated Nov 16, 2026

Chronic Subdural Hematoma Recurrence

A Phase 1/2 interventional study of Dextrose solution and Saline in Chronic Subdural Hematoma and Recurrent, sponsored by Carilion Clinic. Recruiting at 1 site in United States. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Carilion Clinic · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Registered 2 years 9 months after the study started (first participant enrolled Jan 2024, registered Nov 2026).
  • Started Jan 2024; still recruiting 2 years 9 months later.
Updated Nov 16, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
68
Allocation
Randomized
Ages
18 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 22 studies in Hematoma, Subdural, Chronic with a site in United States — 10 open to participants now, 10 under way, none of them phase 3. Hematoma, Subdural, Chronic · United States.

Planned enrollment
6th of 15
68 · median 40
Started
2024
with 2 others
Phase 1/2
Only one
of the 22
Registered
22nd of 22
by date
Lead sponsor
2 of 22
Carilion Clinic

Among the 22 studies in Hematoma, Subdural, Chronic with a site in United States, this one is the 6th largest by planned enrollment of the 15 interventional ones that give a count, is one of 3 that started in 2024, is the only one in phase 1/2, and was the 22nd registered.

Hematoma, Subdural, Chronic

113 studies on the registry are indexed under Hematoma, Subdural, Chronic; 50 are open to participants now.

Browse Hematoma, Subdural, Chronic studies →

Open to participants now

10 of the 22 studies in Hematoma, Subdural, Chronic with a site in United States are open now. Recruiting first, the newest first:

4 more — sign in →

All 10 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 36 Hematoma, Subdural, Chronic studies recruiting now, 26 (72%) set no upper age limit and 1 (3%) stops at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.

This study: 18 Years to 100 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies in Hematoma, Subdural, Chronic with a site in United States, or all of them as a file.
02

Study summary

How can investigators improve recurrence rates of chronic subdural hematomas to reduce need for surgical intervention? Study investigators hypothesize that Dextrose 5% in 0.225% Sodium Chloride (D5 ¼NS) will increase the intracellular brain volume and water content post-operatively, reducing the residual subdural space that is created by evacuation of the chronic subdural hematoma (CSDH), and that this, in turn, will reduce the hematoma volume that will then potentially lead to improved functional outcomes, reduced hospitalization time as well as the reduced rate of symptomatic recurrence requiring redo surgery.

Read the detailed description

The proposed study is a randomized, placebo controlled clinical trial to investigate the effects of D5 ¼NS (treatment) vs. NS (placebo) on residual cSDH volume after surgical drainage via a craniotomy or burr holes.

Participants in the study will be adult patients who had presented with imaging evidence (based on non-contrast head CT) of cSDH requiring surgical evacuation (craniotomy or burr holes). Patients in this study will receive either 5% dextrose ¼Normal Saline (treatment) or Normal Saline (placebo) for 24h after surgery. The study group assignment will be performed based on randomization process prior to the surgery. All the patients will be undergoing a head CT without contrast imaging at 24h after surgery. The residual hematoma volume will be calculated based on XYZ/2 method as previously described (Sucu et al., 2005).

The bedside nursing staff will be provided with either the placebo or D5 ¼NS solutions from the pharmacy in an opaque bag to be administered to the patient after the randomization process has taken place. The procedure for the placebo and treatment solution administration is the same as the standard intravenous fluid administration procedure except the fact of an opaque covering and maintenance of the blinding throughout the process. The bedside nursing staff will administer the intravenous fluid. The infusion rate, as stated, will be 100 cc/h for 24h after SDH evacuation surgery at which time a standard of care head CT without contrast will be obtained. This will be a double-blinded study where blinding will be achieved via the prerandomized enrollment log. Participants signing the consent will be enrolled based on time of enrollment and study ID will be prelinked to a study group of normal saline (placebo) or D51/4NS solution. Pharmacy who will be documenting the treatment allocation and will be issuing the IV fluid for each of the patients will be maintaining the blinding status. The pharmacy staff and coordinator will be the only individuals holding the blinding key which will be released at the official end of the study after all the datapoints have been gathered for all the participants. Additionally, the patients will have basic metabolic panel (BMP as standard of care ) labs drawn every 12 hours during the 24 hour treatment period to assess the electrolyte status and any adverse reactions. The PI and all other study team members, other than the randomizing coordinator, will remain blinded. The unblinded coordinator will not perform any clinical assessments and will not share blinding information with any other team members.

Symptomatic recurrence rates requiring redo surgery within a 90-day period (+/- 7 days) after the initial surgery will be identified via the chart review of each individual study participant.

03

Conditions studied

  • Chronic Subdural Hematoma
  • Recurrent
04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written and voluntarily given
  • If the patient cannot give informed consent, a legally authorized representative may provide it
  • Male or female 18-100
  • Imaging evidence indicative of cSDH
  • The neurosurgical team has determined that the patient requires surgical evacuation of the cSDH

Exclusion criteria

Exclusion Criteria:

  • significant/symptomatic hyperglycemia; specifically diabetic ketoacidosis or fasting blood glucose level >200 mg/dl
  • Patients with significant hyponatremia (Na \<130 mEq/L)
  • Patients who are judged by investigators as being ineligible for participation in the study Patients with a history of relevant drug Patients who receive another drug shortly before acquisition of consent Women who are pregnant or breastfeeding
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
68 participants (estimated)

Study arms

  • Placebo comparator
    normal saline

    normal saline

    Drug: Saline

  • Active comparator
    saline with dextrose (D5 ¼NS solutions)

    saline with dextrose (D5 ¼NS solutions)

    Drug: Dextrose solution

Interventions

  • D5 ¼NS solutions

    Also known as: saline with dextrose (D5 ¼NS solutions)

  • DrugSaline

    normal saline

    Also known as: normal saline

06

What researchers measure

Primary outcomes

  1. Comparative residual CSDH volume (in mm3) measured and calculated using head CT

    Comparative residual CSDH volume (in mm3) measured and calculated using head CT

    Time frame: 24 hours after surgery

Secondary outcomes

  1. ICU and overall hospitalization length of stay

    ICU and overall hospitalization length of stay.

    Time frame: duration of total hospital stay assessed for up to 6 months

  2. Functional improvement as measured using mRS scale scores upon admission

    Functional improvement as measured using mRS scale scores upon admission, scoring from 0-6, low score with no symptoms and 6 indicating death

    Time frame: follow up post surgery assessment up to 6 weeks post release

  3. Symptomatic recurrence rates requiring redo surgery within a 90-day period (+/- 7 days) after the initial surgery

    Symptomatic recurrence rates requiring redo surgery within a 90-day period (+/- 7 days) after the initial surgery

    Time frame: 90 days post surgery

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2024 (actual). Primary completion is estimated for Dec 2027, 47 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 5, 2026
First posted
Nov 16, 2026
StartActual
Jan 31, 2024
Primary completionEst.
Dec 31, 2027
CompletionEst.
Dec 31, 2027
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07937410
Lead sponsor
Carilion Clinic
Responsible party
Eric A. Marvin (Neurosurgeon, Carilion Clinic) — Principal investigator
First posted
Nov 16, 2026
Start date
Jan 31, 2024
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Nov 16, 2026

Study contacts

Jordan Darden, PhD
Contact
jadarden@carilionclinic.org
540-529-7792
Kristine Ravina, MD
Contact
kravina@carilionclinic.org
540-224-5170
Eric Marvin, DO
principal investigator · Carilion Clinic

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Glucose

Start the discussion